ST Pharm Co.,Ltd. (KOSDAQ:237690)

South Korea · Delayed Price · Currency is KRW

93,300

-2,300 (-2.41%)

Oct 2, 2026, 3:30 PM KST

Market Cap	1.95T +6.3%
Revenue (ttm)	386.46B +29.6%
Net Income	76.80B +126.3%
EPS	3,644.39 +114.6%
Shares Out	20.88M
PE Ratio	25.60
Forward PE	24.18
Dividend	500.00 (0.54%)
Ex-Dividend Date	Mar 30, 2026

Volume	62,574
Open	95,000
Previous Close	95,600
Day's Range	92,400 - 96,000
52-Week Range	84,100 - 172,100
Beta	0.31
Analysts	Strong Buy
Price Target	177,777.78 (+90.54%)
Est. Earnings	Oct 30, 2026

About ST Pharm

ST Pharm Co.,Ltd., provides manufacturing services for active pharmaceutical ingredient and intermediate. The company offers small molecule and generics, an ingredient for treating viral infections; oligonucleotide based products, such as siRNA/microRNA, antisense, aptamer, decoys, and other novel oligos; monomer; and mRNA for vaccines and therapeutics. It also offers pre-clinical and bioanalytical research and development solutions. The company was formerly known as Samchully Pharmaceutical Company., Ltd. ST Pharm Co. Ltd. was founded in 1983 ... [Read more]

Industry Medical - Pharmaceuticals

Sector Healthcare

Founded 1983

Employees 655

Stock Exchange KOSDAQ

Ticker Symbol 237690

Full Company Profile

Financial Performance

In 2025, ST Pharm's revenue was 331.68 billion, an increase of 21.16% compared to the previous year's 273.75 billion. Earnings were 54.99 billion, an increase of 58.42%.

Financial Statements

Analyst Summary

According to 9 analysts, the average rating for 237690 stock is "Strong Buy." The 12-month stock price target is ₩177,778, which is an increase of 90.54% from the latest price.

Price Target

₩177,778

(90.54% upside)

Analyst Consensus: Strong Buy

Stock Forecasts